<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27904547</article-id><article-id pub-id-type="pmc">5122181</article-id><article-id pub-id-type="publisher-id">JRMS-21-1</article-id><article-id pub-id-type="doi">10.4103/1735-1995.175144</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The effect of vitamin D administration on serum leptin and adiponectin levels in end-stage renal disease patients on hemodialysis with vitamin D deficiency: A placebo-controlled double-blind clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Naini</surname><given-names>Afsoon Emami</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Vahdat</surname><given-names>Sahar</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Hedaiati</surname><given-names>Zahra Parin</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Shahzeidi</surname><given-names>Safoura</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Pezeshki</surname><given-names>Amir Hossein</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Nasri</surname><given-names>Hamid</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">Department of Nephrology, Division of Nephropathology, Nour Medical, Educational and Therapeutic Center, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Department of Internal Medicine, Isfahan Medical Students Research Center (ISRC), Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff3"><label>2</label>Student of Medicine, Isfahan Medical Students Research Center (ISRC), Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Sahar Vahdat, Department of Nephrology, Division of Nephropathology, Nour Medical, Educational and Therapeutic Center, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="s.vahdat11@yahoo.com">s.vahdat11@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>1</month><year>2016</year></pub-date><volume>21</volume><elocation-id>1</elocation-id><history><date date-type="received"><day>24</day><month>10</month><year>2015</year></date><date date-type="rev-recd"><day>13</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>30</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Journal of Research in Medical Sciences</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>The prevalence of vitamin D deficiency is higher in end-stage renal disease (ESRD) patients compared to healthy populations. This deficiency could lead to several complications with different mechanisms and might result in reduced survival in patients. Leptin and adiponectin are messenger proteins with endocrine secretion from adipocytes and various effects in cellular mechanisms. The goal of this study was to find the effect of vitamin D administration on serum levels of leptin and adiponectin in ESRD patients.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>This double-blind randomized placebo-controlled clinical trial was carried out on 64 ESRD patients on hemodialysis in the Amin and Noor hospitals of Isfahan, Iran. Patients were categorized into two groups, on control and intervention; serum levels of vitamin D, leptin, and adiponectin were measured in both groups before and after the study. The intervention group was treated with vitamin D pearls, while the control group received placebo in the same manner.</p></sec><sec id="st3"><title>Results:</title><p>The mean [standard deviation (SD)] ages of the patients were 62 (21) years and 60 (19) years in the control and treated groups, respectively.</p></sec><sec id="st4"><title>Conclusion:</title><p>The change in serum level of vitamin D was statistically significant in the treatment group but not in the control group. The serum level of leptin was reduced in the treatment group, while the serum level of adiponectin increased significantly, but none of these changes were statistically significant in the control group. This study showed that vitamin D administration is associated with an increase in adiponectin and a decrease in leptin level in ESRD patients.</p></sec></abstract><kwd-group><kwd>Adiponectin</kwd><kwd>chronic kidney disease (CKD)</kwd><kwd>end-stage renal disease (ESRD)</kwd><kwd>leptin</kwd><kwd>vitamin D deficiency</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Adipocytes as a part of the endocrine system secrete several proteins called adipokines into the bloodstream. Adipokines consist of leptin, adiponectin, interleukin (IL)-&#x000df;6, tumor necrosis factor (TNF)&#x003b1;, resistin, and visfatin.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] These proteins play roles in different processes such as food intake, insulin-related functions, energy balance, the coagulation process, angiogenesis, glucose and lipid metabolism, and vascular remodeling. They are also known as a part of pathogenesis for some diseases, vascular atherosclerosis, insulin resistance, and dyslipidemia.[<xref rid="ref3" ref-type="bibr">3</xref><xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref>] The concentration of adipokines is related to body fat mass, i.e., their levels in the body increase with body fat mass, except for adiponectin, which is reduced.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>]</p><p>Adiponectin is a 244-amino acid protein with protective action against atherosclerosis and other cardiovascular diseases and also an antiinflammatory effect.[<xref rid="ref14" ref-type="bibr">14</xref>] Leptin is a 167-amino acid protein with a role in energy balance and nutrition, immune system balance, and inflammatory effect.[<xref rid="ref4" ref-type="bibr">4</xref>]</p><p>Serum levels of adipokines increase in end-stage renal disease (ESRD) patients due to decreased clearance result in increased blood levels.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref13" ref-type="bibr">13</xref>] Another factor contributing to the serum level of adipokines is the level of vitamin D in patients. Elevation in vitamin D level is related to increased adipokine serum level and could limit leptin production in adipocytes.[<xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref>] Increased vitamin D level could also regulate the level of TNF&#x003b1;.[<xref rid="ref18" ref-type="bibr">18</xref>]</p><p>Vitamin D deficiency is more prevalent in ESRD patients on dialysis than in the normal population. This in turn leads to increased morbidity and mortality in these patients. Several studies have been carried out that suggest that vitamin D prescription could lead to enhanced life expectancy, better quality of life, and improvement of other complications in these patients.[<xref rid="ref19" ref-type="bibr">19</xref>]</p><p>The goal to this study was to find the effect of cholecalciferol prescription on leptin and adiponectin levels in ESRD patients.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><sec id="sec2-1"><title>Participants</title><p>This study is a double-blind placebo-controlled randomized clinical trial on ESRD patients on dialysis. The study was carried out in the Amin and Noor Hospitals of Isfahan, Iran between July 2013 and August 2014. Hemodialysis patients aged 18-80 years old with vitamin D deficiency were entered in the study. At the beginning, the complete process was explained to the patients and if they volunteered to participate, a consent form was signed. As the level of vitamin D was measured in all ESRD patients as part of a routine protocol in the Noor and Amin hospitals of Isfahan, the patients with vitamin D levels less than 30 ng/mL were selected as vitamin D deficiency cases and were entered in the study. The patients were categorized into two groups of treatment and control using simple randomization method. The number of patients in both groups was 32 patients.</p></sec><sec id="sec2-2"><title>Study design</title><p>Patients in the treatment group were prescribed 50000 IU vitamin D pearls according to the KDOQI protocol. One 50000-IU weekly dose of vitamin D pearl was given to this group for 12 weeks and the regimen was continued with 50000 IU every 3 weeks.[<xref rid="ref20" ref-type="bibr">20</xref>] Control group patients were given placebo pearls (product of Zahravi Pharmaceutical Co., Iran) with exactly the same sequence. Neither the patients nor the nurses knew which patients received placebo or vitamin D pearls. Patients were followed for 6 months. Serum levels of vitamin D, leptin, and adiponectin were measured for all patients at the beginning of the study and 4 months after that. Leptin and adiponectin levels were evaluated from venous bloods samples using LDN kit (LDN, Nordhorn, Germany) and Boster kit (Boster Bio, USA) respectively by the enzyme-linked immunosorbent assay (ELISA) method at Baradaran Lab., Isfahan.</p><p>Criteria for patient inclusion:</p><p>
<list list-type="bullet"><list-item><p>Age &#x0003e;18 years.</p></list-item><list-item><p>ESRD patients undergoing hemodialysis for at least 3 months.</p></list-item><list-item><p>Patients with vitamin D deficiency (serum level &#x0003c;30 ng/mL).</p></list-item><list-item><p>Consent for entering the study.</p></list-item></list>
</p><p>Criteria for patient exclusion:</p><p>
<list list-type="bullet"><list-item><p>Obesity [body mass index (BMI) &#x0003e;40 based on body weight after dialysis].</p></list-item><list-item><p>Low compliance.</p></list-item><list-item><p>History of malignancy or chemotherapy.</p></list-item><list-item><p>Inflammatory or infectious diseases.</p></list-item><list-item><p>Patients taking antiseizure medications.</p></list-item></list>
</p></sec><sec id="sec2-3"><title>Statistical analysis</title><p>Average levels of vitamin D, leptin, and adiponectin for patients in the control and treatment groups before and after the study were analyzed by gender using paired <italic>t</italic>-test and two-way repeated measured analysis of variance (ANOVA) on IBM SPSS Statistics for Windows, Version 20.0., Armonk, NY: IBM Corp.</p></sec><sec id="sec2-4"><title>Ethical considerations</title><p>The current study was approved ethically by the Research Ethics Committee of the Research Department at Isfahan University of Medical Sciences. All patients were fully informed about the course of the study, potential side effects, and other such considerations. The research followed the tenets of the Declaration of Helsinki. The authors made certain that all participants made an informed decision to enter the study. The specific questionnaire for clinical trials was filled by the Research Department. The project also registered at the Iranian Registry of Clinical Trials (IRCT): IRCT201505152417.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><sec id="sec2-5"><title>Characteristic and demographic data of patients</title><p>Demographic parameters were similar between the two groups, with ages ranging 20-78 years, with 24 patients (37.5%) aged 51-60 years of age. The participants consisted of 32 male (50%) and 32 female (50 %) patients [<xref ref-type="fig" rid="F1">Figure 1</xref> and <xref ref-type="table" rid="T1">Table 1</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Clinical trial diagram</p></caption><graphic xlink:href="JRMS-21-1-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Basic characteristics of the study population</p></caption><graphic xlink:href="JRMS-21-1-g002"/></table-wrap></sec><sec id="sec2-6"><title>The effect of vitamin D administration on serum levels of leptin and adiponectin</title><p>Serum levels of vitamin D, leptin, and adiponectin were measured in all patients before and after the study [<xref ref-type="table" rid="T2">Table 2</xref>]. As is seen in <xref ref-type="table" rid="T2">Table 2</xref>, the level of vitamin D in the treatment group was significantly increased (<italic>P</italic> = 0.001), while these changes were not statistically significant in the control group (<italic>P</italic> &#x02265; 0.05). Before the study, 7 patients in the control group and 5 patients in the treatment group suffered from vitamin D deficiency (serum level &#x02264;10 ng/dL), whereas after the study, all of these patients had a vitamin D level of over 10 ng/dL. None of the patients had hypervitaminosis D during the course of the study.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Serum 25 (OH) vitamin D levels of the patients before and after the study in both groups</p></caption><graphic xlink:href="JRMS-21-1-g003"/></table-wrap><p>Average serum levels of leptin in the control group before and after treatment were 35.020 ng/mL and 34.042 ng/mL, respectively (<italic>P</italic> &#x02265; 0.05), while in the treatment group these levels were 37.052 ng/mL and 32.676 ng/mL, respectively (<italic>P</italic> = 0.001). In other words, the decline in the serum level of leptin was statistically significant in the treatment group but not in the control group.</p><p>In addition, the average level of adiponectin in the control group before and after treatment were 4.01 ng/mL and 4.07 ng/mL, respectively (<italic>P</italic> &#x02265; 0.05), while in the treatment group, these levels were 4.35 ng/mL and 4.92 ng/mL in that order (<italic>P</italic> = 0.001). This shows a significant elevation in adiponectin level in the treatment group.</p><p>On statistical analysis, the average change in serum levels of leptin and adiponectin based on gender in the two groups demonstrate that sex has no significant effect on these levels. Apart from vitamin D administration, all other factors have a <italic>P</italic> value of over 0.05. The fact that the difference between means in two groups has a <italic>P</italic> value of below 0.05 shows that the difference in the average change of leptin and adiponectin levels in the two groups is statistically significant [<xref ref-type="table" rid="T3">Table 3</xref>]. Furthermore, the effects of age, BMI, and underlying factors for ESRD on changes in serum levels of these two markers were not statistically significant.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Adiponectin and leptin serum levels before and after the study in both groups (mean &#x000b1; standard deviation)</p></caption><graphic xlink:href="JRMS-21-1-g004"/></table-wrap></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>The goal of this study was to determine the effect of vitamin D administration on serum levels of leptin and adiponectin. It has been show that administration of vitamin D leads to decline in serum leptin level and rise in serum adiponectin level.</p><p>Administration of 650000 IU vitamin D <italic>per os</italic> in the treatment group resulted in an increase in serum level of vitamin D to 79 ng/dL, whereas administration of the placebo resulted in no significant change in vitamin D level in the control group. This study also showed that other factors such as gender, BMI, age, and underlying cause of ESRD have no effect in determining serum leptin and adiponectin levels.</p><p>Leptin and adiponectin are hormones that are secreted in blood by adipocytes, influencing various tissues and resulting in several different outcomes in the human body.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] Leptin plays a role in nutrition, energy balance, triggering inflammation, and immune modulation. Adiponectin has antiatherogenic and antiinflammatory characteristics, and also increases response to insulin.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] Various factors could change the levels of these hormones in serum. One of the most substantial ones is body fat mass. Generally, all adipokines are increased with an increase in body fat mass except for adiponectin. Other factors influencing the level of these hormones are age, sex hormone levels, and inflammatory process.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>]</p><p>The level of adipokines are generally increased in ESRD patients due to their reduced renal clearance while body fat mass still plays a significant role in adipokine levels in these patients too. The level of adipokines is further increased in ESRD patients and this could in part result in changes in the metabolism of patients.[<xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref><xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref>]</p><p>Several studies have been carried out on the effect of various factors on leptin and adiponectin and other adipokines in ESRD patients. Aguilera <italic>et al</italic>. demonstrated the association between triglyceride (TG), cholesterol, and serum level of adiponectin.[<xref rid="ref25" ref-type="bibr">25</xref>] Malyszko <italic>et al</italic>. showed that leptin levels could also be related to platelet aggregation and hemostatic parameters.[<xref rid="ref26" ref-type="bibr">26</xref>] Several other studies have shown the association between the rise of vitamin D levels with an increase in adiponectin levels and a decrease in leptin levels.[<xref rid="ref27" ref-type="bibr">27</xref><xref rid="ref28" ref-type="bibr">28</xref><xref rid="ref29" ref-type="bibr">29</xref><xref rid="ref30" ref-type="bibr">30</xref>]</p><p>The current study has established that vitamin D administration in ESRD patients leads to a rise in adiponectin level and reduction of leptin level.</p><p>As adiponectin results in protective effects against atherosclerosis, cerebrovascular accident (CVA), chronic inflammation, and increased sensitivity to insulin, a decrease in its serum level could improve prognosis in ESRD patients.[<xref rid="ref31" ref-type="bibr">31</xref>] Moreover, due to the effects of leptin in increasing appetite, weight gain, triggering of inflammation, rising heart rate and blood pressure and hence increasing the risk of myocardial infarction (MI) and CVA, a reduction in serum level of this marker could improve survival in ESRD patients.</p><p>Oral antidiabetes medications such as metformin could affect serum levels of leptin and adiponectin; however, in the present study, due to their chronic kidney disease (CKD), all subjects were only on treatment with Insulin and therefore were not excluded from the study.</p><p>Some of the downsides to this study include it being undertaken in a hemodialysis center that omits subjects on peritoneal dialysis. The small sample size is another shortcoming, and we suggest further studies be carried out with larger sample sizes of ESRD patients.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>As a conclusion, it could be stated that the administration of vitamin D supplements in ESRD patients could result in an increase in adiponectin and a decrease in leptin level. This could in turn reduce the risk of other ESRD complications. Due to the very few side effects and the various benefits, vitamin D administration in these patients could lead to enhanced survival overtime.</p><sec id="sec2-7"><title>Financial support and sponsorship</title><p>This study was funded by Isfahan University of Medical Sciences (Research project number: 293286).</p></sec><sec id="sec2-8"><title>Conflicts of interest</title><p>The authors have no conflicts of interest.</p></sec></sec><sec id="sec1-6"><title>AUTHOR'S CONTRIBUTION</title><p>AHP contributed in conception of the work, study design, writing the article, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work PM contributed in the conception of the work, drafting and revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. SV contributed in conception of the work, study design, samples and data collection, data analysis, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work PM contributed in the conception of the work, drafting and revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. AE contributed in conception of the work, study design, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work PM contributed in the conception of the work, drafting and revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. SSh contributed in conception of the work, sample collecting, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work PM contributed in the conception of the work, drafting and revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. HN contributed in study design, article writing, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work PM contributed in the conception of the work, drafting and revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. ZPH contributed in Conception of the work, study design, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work PM contributed in the conception of the work, drafting and revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kershaw</surname><given-names>EE</given-names></name><name><surname>Flier</surname><given-names>JS</given-names></name></person-group><article-title>Adipose tissue as an endocrine organ</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>2548</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">15181022</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halaas</surname><given-names>JL</given-names></name><name><surname>Gajiwala</surname><given-names>KS</given-names></name><name><surname>Maffei</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>SL</given-names></name><name><surname>Chait</surname><given-names>BT</given-names></name><name><surname>Rabinowitz</surname><given-names>D</given-names></name><etal/></person-group><article-title>Weight-reducing effects of the plasma protein encoded by the obese gene</article-title><source>Science</source><year>1995</year><volume>269</volume><fpage>543</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7624777</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Said</surname><given-names>S</given-names></name><name><surname>Hernandez</surname><given-names>GT</given-names></name></person-group><article-title>The link between chronic kidney disease and cardiovascular disease</article-title><source>J Nephropathol</source><year>2014</year><volume>3</volume><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">25093157</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gainsford</surname><given-names>T</given-names></name><name><surname>Willson</surname><given-names>TA</given-names></name><name><surname>Metcalf</surname><given-names>D</given-names></name><name><surname>Handman</surname><given-names>E</given-names></name><name><surname>McFarlane</surname><given-names>C</given-names></name><name><surname>Ng</surname><given-names>A</given-names></name><etal/></person-group><article-title>Leptin can induce proliferation, differentiation and functional activation of hemopoietic cells</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>14564</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8962092</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Considine</surname><given-names>RV</given-names></name><name><surname>Sinha</surname><given-names>MK</given-names></name><name><surname>Heiman</surname><given-names>ML</given-names></name><name><surname>Kriauciunas</surname><given-names>A</given-names></name><name><surname>Stephens</surname><given-names>TW</given-names></name><name><surname>Nyce</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Serum immunoreactive-leptin concentrations in normal-weight and obese humans</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><fpage>292</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8532024</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Biersmith</surname><given-names>M</given-names></name><name><surname>Tolouian</surname><given-names>R</given-names></name></person-group><article-title>Obesity and kidney protection</article-title><source>J Nephropathol</source><year>2014</year><volume>3</volume><fpage>91</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25093156</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auwerx</surname><given-names>J</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name></person-group><article-title>Leptin</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>737</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">9504534</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>GM</given-names></name><name><surname>Matarese</surname><given-names>G</given-names></name><name><surname>Howard</surname><given-names>JK</given-names></name><name><surname>Baker</surname><given-names>RJ</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name><name><surname>Lechler</surname><given-names>RI</given-names></name></person-group><article-title>Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression</article-title><source>Nature</source><year>1998</year><volume>394</volume><fpage>897</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">9732873</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouloumi&#x000e9;</surname><given-names>A</given-names></name><name><surname>Marumo</surname><given-names>T</given-names></name><name><surname>Lafontan</surname><given-names>M</given-names></name><name><surname>Busse</surname><given-names>R</given-names></name></person-group><article-title>Leptin induces oxidative stress in human endothelial cells</article-title><source>FASEB J</source><year>1999</year><volume>13</volume><fpage>1231</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10385613</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nouri</surname><given-names>P</given-names></name><name><surname>Nasri</surname><given-names>H</given-names></name></person-group><article-title>Irisin and kidney disease; new concepts</article-title><source>J Renal Endocrinol</source><year>2015</year><volume>1</volume><fpage>e03</fpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agata</surname><given-names>J</given-names></name><name><surname>Masuda</surname><given-names>A</given-names></name><name><surname>Takada</surname><given-names>M</given-names></name><name><surname>Higashiura</surname><given-names>K</given-names></name><name><surname>Murakami</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>High plasma immunoreactive leptin level in essential hypertension</article-title><source>Am J Hypertens</source><year>1997</year><volume>10</volume><fpage>1171</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9370390</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordfors</surname><given-names>L</given-names></name><name><surname>L&#x000f6;nnqvist</surname><given-names>F</given-names></name><name><surname>Heimb&#x000fc;rger</surname><given-names>O</given-names></name><name><surname>Danielsson</surname><given-names>A</given-names></name><name><surname>Schalling</surname><given-names>M</given-names></name><name><surname>Stenvinkel</surname><given-names>P</given-names></name></person-group><article-title>Low leptin gene expression and hyperleptinemia in chronic renal failure</article-title><source>Kidney Int</source><year>1998</year><volume>54</volume><fpage>1267</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">9767543</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>JW</given-names></name><name><surname>Yen</surname><given-names>CJ</given-names></name><name><surname>Chiang</surname><given-names>HW</given-names></name><name><surname>Hung</surname><given-names>KY</given-names></name><name><surname>Tsai</surname><given-names>TJ</given-names></name><name><surname>Wu</surname><given-names>KD</given-names></name></person-group><article-title>Adiponectin in peritoneal dialysis patients: A comparison with hemodialysis patients and subjects with normal renal function</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>43</volume><fpage>1047</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">15168385</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Kuriyama</surname><given-names>H</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>2473</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10604883</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Soltani-Bejnood</surname><given-names>M</given-names></name><name><surname>Quignard-Boulange</surname><given-names>A</given-names></name><name><surname>Massiera</surname><given-names>F</given-names></name><name><surname>Teboul</surname><given-names>M</given-names></name><name><surname>Ailhaud</surname><given-names>G</given-names></name><etal/></person-group><article-title>The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system</article-title><source>J Biomed Biotechnol 2006</source><year>2006</year><comment>27012</comment></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasue</surname><given-names>S</given-names></name><name><surname>Masuzaki</surname><given-names>H</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Ishii</surname><given-names>T</given-names></name><name><surname>Kozuka</surname><given-names>C</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: Impact of nutritional status and adipocyte hypertrophy</article-title><source>Am J Hypertens</source><year>2010</year><volume>23</volume><fpage>425</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">20057360</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittas</surname><given-names>AG</given-names></name><name><surname>Harris</surname><given-names>SS</given-names></name><name><surname>Stark</surname><given-names>PC</given-names></name><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name></person-group><article-title>The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>980</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17277040</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>KC</given-names></name><name><surname>Chu</surname><given-names>A</given-names></name><name><surname>Go</surname><given-names>VL</given-names></name><name><surname>Saad</surname><given-names>MF</given-names></name></person-group><article-title>Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction</article-title><source>Am J Clin Nutr</source><year>2004</year><volume>79</volume><fpage>820</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15113720</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>D</given-names></name><name><surname>Byham-Gray</surname><given-names>L</given-names></name><name><surname>Lewis</surname><given-names>E</given-names></name><name><surname>McCaffrey</surname><given-names>S</given-names></name></person-group><article-title>Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D 2) in stage 5 chronic kidney disease patients</article-title><source>J Ren Nutr</source><year>2008</year><volume>18</volume><fpage>375</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">18558303</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><article-title>National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease</article-title><source>Am J Kidney Dis</source><year>2003</year><volume>42</volume><issue>Suppl 3</issue><fpage>S1</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">14520607</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Kihara</surname><given-names>S</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Kuriyama</surname><given-names>H</given-names></name><etal/></person-group><article-title>Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>1296</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">10982546</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouchi</surname><given-names>N</given-names></name><name><surname>Shibata</surname><given-names>R</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name></person-group><article-title>Cardioprotection by adiponectin</article-title><source>Trends Cardiovasc Med</source><year>2006</year><volume>16</volume><fpage>141</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16781946</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Hollis</surname><given-names>BW</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name></person-group><article-title>25-hydroxyvitamin D and risk of myocardial infarction in men: A prospective study</article-title><source>Arch Intern Med</source><year>2008</year><volume>168</volume><fpage>1174</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">18541825</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>TJ</given-names></name><name><surname>Pencina</surname><given-names>MJ</given-names></name><name><surname>Booth</surname><given-names>SL</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name><name><surname>Ingelsson</surname><given-names>E</given-names></name><name><surname>Lanier</surname><given-names>K</given-names></name><etal/></person-group><article-title>Vitamin D deficiency and risk of cardiovascular disease</article-title><source>Circulation</source><year>2008</year><volume>117</volume><fpage>503</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">18180395</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilera</surname><given-names>A</given-names></name><name><surname>Bajo</surname><given-names>MA</given-names></name><name><surname>Rebollo</surname><given-names>F</given-names></name><name><surname>D&#x000ed;ez</surname><given-names>JJ</given-names></name><name><surname>D&#x000ed;az</surname><given-names>C</given-names></name><name><surname>Paiva</surname><given-names>A</given-names></name><etal/></person-group><article-title>Leptin as a marker of nutrition and cardiovascular risk in peritoneal dialysis patients</article-title><source>Adv Perit Dial</source><year>2002</year><volume>18</volume><fpage>212</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12402621</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malyszko</surname><given-names>J</given-names></name><name><surname>Wolczynski</surname><given-names>S</given-names></name><name><surname>Malyszko</surname><given-names>J</given-names></name><name><surname>Mysliwiec</surname><given-names>M</given-names></name></person-group><article-title>Leptin correlates with some hemostatic parameters in CAPD patients</article-title><source>Nephron</source><year>2001</year><volume>92</volume><fpage>721</fpage><lpage>4</lpage></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasri</surname><given-names>H</given-names></name><name><surname>Ardalan</surname><given-names>MR</given-names></name><name><surname>Rafieian-Kopaei</surname><given-names>R</given-names></name></person-group><article-title>On the occasion of world hypertension day 2014</article-title><source>J Parathyr Dis</source><year>2014</year><volume>2</volume><fpage>19</fpage><lpage>20</lpage></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rafieian-Kopaei</surname><given-names>M</given-names></name><name><surname>Nasri</surname><given-names>H</given-names></name></person-group><article-title>Association of serum lipids with levels of leptin in hemodialysis patients</article-title><source>J Nephropharmacol</source><year>2013</year><volume>2</volume><fpage>17</fpage><lpage>20</lpage></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaderian</surname><given-names>SB</given-names></name><name><surname>Beladi-Mousavi</surname><given-names>SS</given-names></name></person-group><article-title>The role of diabetes mellitus and hypertension in chronic kidney disease</article-title><source>J Renal Inj Prev</source><year>2014</year><volume>3</volume><fpage>109</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">25610891</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastegari</surname><given-names>E</given-names></name><name><surname>Nasri</surname><given-names>H</given-names></name></person-group><article-title>Association of serum leptin with serum C-reactive protein in hemodialysis patients</article-title><source>J Nephropharmacol</source><year>2012</year><volume>1</volume><fpage>19</fpage><lpage>21</lpage></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidari</surname><given-names>M</given-names></name><name><surname>Nasri</surname><given-names>P</given-names></name><name><surname>Nasri</surname><given-names>H</given-names></name></person-group><article-title>Adiponectin and chronic kidney disease; a review on recent findings</article-title><source>J Nephropharmacol</source><year>2015</year><volume>4</volume><fpage>57</fpage><lpage>62</lpage></element-citation></ref></ref-list></back></article>